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Abstract
Background: Haemodialysis (HD) is a life-sustaining treatment for patients with end-stage renal disease (ESRD).
HD can bring about significant impairment in health-related quality of life (HRQOL) and outcomes. Therefore, we
sought to describe the patterns of HRQOL and determine the independent factors associated with poor HRQOL in
Palestinian patients on HD.
Methods: A multicenter cross-sectional study was performed from June 2014 to January 2015 using the EuroQOL-5
Dimensions instrument (EQ-5D-5L) for the assessment of HRQOL. ESRD patients undergoing HD in all dialysis
centres in the West Bank of Palestine were approached and recruited for this study. Multiple linear regression
was carried out to identify factors that were significantly associated with HRQOL.
Results: Two hundred and sixty-seven patients were participated in the current study giving response rate of
96 %. Overall, 139 (52.1 %) were male, and the mean ± standard deviation age was 53.3 ± 16.2 years. The reported HRQOL
as measured by mean EQ-5D-5L index value and Euro QOL visual analogue scale (EQ-VAS) score was 0.37 ± 0.44 and
59.38 ± 45.39, respectively. There was a moderate positive correlation between the EQ-VAS and the EQ-5D-5L index value
(r = 0.42, p < 0.001). The results of multiple linear regression showed a significant negative association between HRQOL
with age, total number of chronic co-morbid diseases and the total number of chronic medications. However,
a significant positive association was found between HRQOL with male gender, university education level and
patients who live in village.
Conclusion: Our results provided insight into a number of associations between patient variables and their
HRQOL. Healthcare providers should be aware of low HRQOL among patients with no formal education, female
gender, patient’s residents of refugee camps, multiple co-morbid diseases, multiple chronic medications, and elderly
patients to improve their quality of life.
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Background
Chronic kidney disease (CKD) is a growing worldwide
public health concern [1, 2]. It is characterised by an ir-
reversible worsening of renal function that could lead to
end-stage renal disease (ESRD), which necessitates treat-
ment with renal replacement therapy (RRT) such as
renal transplant or haemodialysis (HD) [3, 4]. HD is one
of the most effective therapeutic techniques for pa-
tients with ESRD second to renal transplantation, but
is expensive and burdensome therapy for patients
with ESRD [1, 2, 5].
In the United States of America (USA), the number of
newly reported ESRD cases in 2013 was 117,162 corre-
sponding to an unadjusted incidence rate of 363 per mil-
lion per year [6, 7]. In the USA, 88.2 % of all incident
cases started with RRT with HD, 9.0 % initiated with
peritoneal dialysis, and 2.6 % got a pre-emptive kidney
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transplant [6, 8]. In the West Bank of Palestine, the total
number of patients with ESRD has increased notably
over the last several years [9]. In 2014, the total reported
number of ESRD patients undergoing HD in the West
Bank was 1104 patients, representing an increase of
77.5 % compared to reported numbers in 2011 [10].
Previous reports have confirmed that ESRD patients
undergoing HD have lower health-related quality of life
(HRQOL) compared with compared with a normative
sample [11–21]. Patients with ESRD undergoing HD are
prone to several complications such as depression, in-
flammation, and malnutrition [21, 22]. Up to now, too
little attention has been paid to document the HRQOL
of patients with ESRD in the Middle East [12, 23, 24]. It
has been shown that improving the quality of treatment
in patients with ESRD can minimize the development
and/or severity of complications and therefore improve
patients’ HRQOL [25–27].
Health-related quality of life is a cultural concept as
revealed by the difference in association between
HRQOL and clinical outcomes such as compliance, or
patient survival [28–30]. HRQOL is recognized as an es-
sential health outcome for studies assessing the quality
of healthcare, evaluating the impact of illness, and ana-
lyses of cost-effectiveness [31–33]. In addition, it has
been shown that HEQOL is clinically important for
improving dialysis outcome in patients on HD [34, 35].
Although several studies were carried out and pub-
lished about HRQOL in different disease populations in
Palestine such as diabetic or hypertensive patients
[36, 37], no such studies were carried out among HD
patients in Palestine. Therefore, we performed the
present study to describe the patterns of HRQOL and
to determine the independent factors associated with
poor HRQOL in Palestinian patients with HD.
Methods
Study design
A multicenter cross-sectional study was carried out from
June 2014 to January 2015.
Study setting
Patients were recruited from all dialysis centres in West
Bank, Palestine. We collated related information about
the distribution of the population from the Palestinian
Central Bureau of Statistics and Ministry of Health [38].
Study population, sampling procedure and sample size
calculation
The Healthcare sector in Palestine is primarily managed
by the Government through the Palestinian Ministry of
Health (PMOH). There are 10 functioning dialysis cen-
tres in West-Bank, Palestine. All the dialysis centres are
on hospital campus and varies in size between one-
machine to 32-machine centres. The PMOH runs nine
out of the 10 available dialysis facilities [10]. At the time
of the study, there were 740 dialysis patients served on
160 HD machines [38]. For the purpose of this study,
sample size was detrmined using a Raosoft sample size
calculator, which is a web-based calculator [39]. A sam-
ple size of 254 patients was considered to achieve a 5 %
margin of error and a 95 % confidence level assuming
that 50 % of patients answered each question correctly.
The sample size was increased by 5–10 % to account for
the non-response rate. Two hundred and seventy seven
patients were selected using a convenience quota sam-
pling method proportional to the number of patients in
each dialysis centre. The inclusion criteria were as follows:
(1) patients 18 years of age or older; (2) confirmed diagno-
sis of ESRD by medical file; and (3) on regular HD therapy
for a minimum of 3 months prior to the interview. Pa-
tients were excluded if they lacked the mental or physical
capacity to communicate with interviewer.
Data collection instrument
Data were collected using a questionnaire containing two
sections, a socio-demographic and clinical history section
and a validated Arabic version of HRQOL section [40].
Details regarding age, gender, body mass index (BMI)
quartiles calculated from height and weight, educational
level, household monthly income were obtained, resi-
dency, living status, smoking status [“light smoker”: (1 to 9
cigarettes/day), “moderate smoker”: (10 to 19 cigarettes/
day), and “heavy smoker”: (≥20 cigarettes/day) [41]], mari-
tal status, occupation, dialysis vintage (length of time on
dialysis treatment), average duration of dialysis session,
total number of medications for chronic use, and the total
number of chronic diseases. We categorised BMI as obese
(BMI ≥ 30 kg/m2), overweight (BMI = 25 to <30 kg/m2),
normal (BMI = 18.5 to <25 kg/m2), or underweight (BMI
< 18.5 kg/m2) [42]. To determine the health status, the 5-
level EuroQoL Group’s 5-dimension (EQ-5D-5L) ques-
tionnaire was used. The EQ-5D instrument was developed
by the Euro QOL Group. The EQ-5D includes a 5-item
descriptive system to calculate the EQ-5D index score and
the EQ visual analogue scale (EQ-VAS) that allows the
patients to judge their current health status during intra-
dialysis from 0 to 100. The measuring principle of the
instrument was described in detail in the previous works
by the investigators [36, 37, 43]. The Arabic version of
EQ-5D [40] was provided by using Euro QOL guidelines
[44]. The study was registered with Euro QOL and per-
mission was given for its use (ID: 8537, approval date:
April 7, 2014).
Data collection procedure
Two hundred and seventy seven patients were recruited
and interviewed face to face. We tried to make each
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interviewee feel as comfortable as possible. Face-to-face
interview was used to provide researchers with an op-
portunity to collect as complete data as possible and to
overcome non-response by those who cannot read.
Interviews were performed by trained clinical pharmacy
students. Data collection method was pre-tested to
check for the clarity of questions in a pilot study of 16
patients was tested on eight medical files that were not
included in the final anslysis. All the comments noted in
the pilot study were taken into consideration and a
modified questionnaire was reviewed by experts in the
field of quality of live (QOL) to ensure content validity
of data collection form in relations to factors that might
be associated with QOL in ESRD population. The in-
ternal consistency of the EQ-5D instrument was found
to be 0.84 which showed high reliability of the EQ-5D
instrument.
Ethical approval
The study protocol was approved by the Ethics Commit-
tee of An-Najah National University, and the local health
authorities that had jurisdiction over the local study
population. The interview content was described to re-
spondents, and an informed verbal consent was obtained
before the start of the interview.
Statistical analysis
Data were analysed using SPSS (SPSS Inc., Chicago, IL,
USA) programme version 15. Results were reported as
mean ± SDs or as frequencies and percentages or as a
median with a range of values (lower-upper quartiles)
wherever appropriate. Data that were not normally dis-
tributed were analysed using the Mann-Whitney U test
or Kruskal-Wallis test according to the number of
groups to compare. The Kolmogorov-Smirnov test was
used to assess normality of distribution of data. The
Pearson correlation coefficient was used to assess the
correlation between the reported EQ-VAS scores and
EQ-5D-5L index values. Multiple linear regression was
carried out to identify factors that were significantly
associated with HRQOL. Multiple linear regression was
carried out to identify factors that were significantly
associated with HRQOL (dependent factor). The inde-
pendent factors were socio-demographic, and HD re-
lated clinical factors. A dummy coding of 0 and 1 was
used to enter the nominal independent variables such as
gender, BMI, educational level, residency, and occupa-
tion into the regression model. Variables with a p < 0.05
in univariate analysis were entered in the regression
model. The significance level was predetermined at p
level < of 0.05 for all tests. Variance inflation factors
(VIF) and tolerance index were conducted to assess col-
linearity between independent variables. The internal
consistency reliability of the study scale was assessed
using Cronbach’s alpha values. EQ-5D was scored to cal-
culate the index value using the value sets (weights)
from the existing United Kingdom general population
scoring algorithm (i.e. EQ-5D-5L Crosswalk Index Value
Calculator [45]). We used the UK value set for three rea-
sons; first, to present the health status as a continuous
variable; second, due to absence of a locally or regionally
appropriate set of values; and lastly to make the com-
parison more reasonable because most published studies
at local or regional level used the UK value set as sug-
gested by EuroQol Group the EQ-5D [12, 37, 46].
Results
Socio-demographic and clinical characteristics
Two hundred and sixty-seven patients were participated
in the current study giving response rate of 96 %. Over-
all, 139 (52.1 %) were male, and the mean (standard
deviation) age was 53.3 (16.2) years. 177 patients (66.3 %)
were on dialysis for less than four years. There were 204
patients (76.4 %) who were dialysed three times weekly
among which 198 patients (74.2 %) stayed on dialysis
three hours. The mean duration of disease was 3.4 ±
3.7 year. The majority of patients 197 (73.8 %) took their
medication by themselves, 116 (43.4 %) had three or more
chronic co-morbid diseases, and 222 (83.1 %) were on
four or more chronic medications. The mean number of
chronic co-morbid diseases was 2.4 ± 1.6 and the mean
number of chronic medications was 6.5 ± 2.8. Overall,
52.7 % of study participants were either overweight or
obese (28.1 % were overweight and 24.6 % were obese).
Being obese was significantly more prevalent in females
(14.8 %) as compared to males (9.8 %); (p value = 0.042).
The socio-demographic and clinical characteristics of the
study participants are displayed in Table 1.
EQ-5D health status
The reported HRQOL as measured by mean EQ-5D-5L
index value and EQ-VAS score was 0.37 ± 0.44 and
59.38 ± 45.39, respectively. There was a moderate posi-
tive correlation between the EQ-VAS and the EQ-5D-5L
index value (r = 0.42, p < 0.001). The distribution of
reported no problems across dimensions of QOL was as
follows: mobility 73 (27.3 %), usual activities 100
(37.5 %), self-care 146 (54.7 %), pain/discomfort 68
(25.5 %) and anxiety/depression 94 (35.2 %); (Fig. 1). A
total of 178 states of health were reported by the partici-
pants. We found that 17 (6.4 %) participants reported no
problems for any dimension, and 9 (3.4 %) patients
reported very severe difficulty for all five dimensions.
EQ-5D-5L index values
The median EQ-5D-5L index value was 0.41 (interquartile
range: 0.06-0.77). Tables 2 showed that there were signifi-
cant differences between participant groups according to
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age, BMI, education level, residency and total co-morbid
disease, as well as gender, occupation, and total number of
chronic medication (p-value < 0.05). No significant differ-
ences were found between participants according to in-
come, living status, marital status, dialysis vintage, dialysis
session duration, smoking status, and transplantation
history.
EQ-VAS score
The median EQ-VAS score was 50 (interquartile range:
50–70). As seen in Tables 3, there were significant differ-
ences between participant groups according to age and
total co-morbid diseases, as well as gender, and total
number of chronic medications (p-value < 0.05). Patients
older than 60 years had a lower EQ-VAS score than
those younger than 60. In addition, male gender was as-
sociated with higher EQ-VAS value compared to female.
The study found that EQ-VAS score decreased as the
total number of chronic medication increased and as il-
lustrated in Table 3 increased co-morbid diseases had
the lowest EQ-VAS score.
After adjustment for covariates, regression coefficients
indicated significant associations between some of the
independent variables and EQ-5D index score in com-
parison to a reference category for categorical variables
or with one unit increase of a continuous variable. This
model explained about 37 % of the variance in EQ-5D
scores. As shown in Table 4, age, total number of
chronic comorbid diseases and the total number of
Table 1 Socio-demographic and clinical characteristics of the
study sample
Variable Frequency (%) N (267)
Age category
< 30 34 (12.7)
30–60 136 (50.9)















High (more than 1000 JDb) 10 (3.7)
Moderate (400–1000 JD) 90 (33.7)
Low (less than 400 JD) 167 (62.5)
Living





With family 249 (93.3)
Marital status






Non smoker 227 (85)
Light smoker 19 (7.1)
Moderate smoker 17 (6.4)
Heavy smoker 4 (1.5)
Dialysis vintage (Years)
< 4 177 (66.3)
≥ 4 90 (33.7)
Dialysis per week
Table 1 Socio-demographic and clinical characteristics of the
study sample (Continued)
≤ 2 26 (9.7)
3 204 (76.4)
≥ 4 37 (13.9)
Dialysis session duration (hours)
< 4 198 (74.2)








≥ 3 116 (43.4)
Chronic medications (per day)
< 4 45 (16.9)
≥ 4 222 (83.1)
Abbreviations: BMI body mass index, JD Jordanian Dinar
aData were missing from 11 patients
b1 Jordanian Dinar (JD) equals 1.41 US Dollar
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chronic medications were negatively associated with EQ-
5D scores, whereas male gender, university education
level and patients who live in village were positively as-
sociated with the EQ-5D scores. The range of VIF was
from 1.015 to 1.465 which indicated absence of multicol-
linearity between independent variables.
Discussion
This study provided a comprehensive analysis of
HRQOL among ESRD patients undergoing HD in the
West Bank of Palestine. HRQOL was assessed using the
EQ-5D Overall, this study indicated that the main socio-
demographic factors associated with HD-related QOL
were old age, female gender, obesity, residency in a refu-
gee camp, unemployment, low income, and having no
formal education. Review of literature indicated that the
EQ-5D has been used to measure HRQOL among ESRD
patients undergoing HD in different countries [11–19].
The construct validity, reliability, and responsiveness of
the EQ-5D have been recognized widely in both specific
and general disease populations [47, 48]. Furthermore,
Wasserfallen et al. [49] showed that using a generic
QOL instrument EQ-5D was well-accepted, and easy to
use for assessing HRQOL among ESRD patients under-
going HD due to the shorter completion time compared
with other generic instruments.
In the current study, we found that mean EQ-5D score
among ESRD patients undergoing HD was 0.37 ± 0.44
while findings from studies that used the same instru-
ments in Korean, Japanese, Taiwan, and Singaporean
patients were 0.704 ± 0.199 [17], 0.75 ± 0.17 [18], 0.65 ±
0.23 [13], and 0.60 ± 0.21 [20], respectively. Several so-
cioeconomic and healthcare system related factors could
affect HRQOL among ESRD patients undergoing HD.
Some of these variations in EQ-5D score could be ex-
plained by differences in the main sociodemographic
and clinical characteristics of recruited participants such
as; age, duration of HD and presence of comorbid dis-
eases. Furthermore, many patients, particularly in devel-
oping countries, frequently do not seek medical advice
until other debilitating symptoms or complications ap-
peared, thus, delay in diagnosis and therapy can directly
increase the number of complications and therefore
leading to reduction in patient’s HRQOL [50].
In our study, there was a modest positive correlation
between the EQ-5D index values and reported EQ-VAS
scores. Several studies suggested that individual experi-
ences that are assessed by different rating scales such as
the EQ-5D-5L and EQ-VAS may result in slightly differ-
ent outcomes [12, 51, 52]. In addition, Saffari et al. [12]
declared that when contributors were asked to select
their health status using five dimensions, accuracy in
outcomes is probable than when using only one overall
dimension of health status.
Our results demonstrated that increased age was asso-
ciated with lower HRQOL. Similar previous studies have
reported the same findings, for instance, Kang et al.’s
[17] study using EQ-5D found age was a significant fac-
tor determining HRQOL of Korean HD patients. Youn-
ger patients (<30 years) in the current study reported
significantly better HRQOL, possibly because of the
short duration of disease, and minor complications [37].
According to another study, older age was the most im-
portant predictor of lower QOL and health status [12].
Our study found that female gender was significantly
associated with lower mean EQ-5D scores than male
Fig. 1 Distribution of health-related quality of life measures in different European Quality of Life scale 5 (EQ-5D) dimensions
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Table 2 EQ-5D total score by socio-demographic and clinical variables (n = 267)
Variable Frequency
(%) N = 267
EQ-5D index score P-value
Mean ± SD Median [interquartile range]
Age category
< 30 34 (12.7) 0.69 ± 0.28 0.79 [0.47–0.88] 0.001a
30–60 136 (50.9) 0.44 ± 0.43 0.55 [0.18–0.77]
> 60 97 (36.3) 0.17 ± 0.40 0.15 [0.13–0.56]
Gender
Male 139 (52.1) 0.46 ± 0.41 0.85 [0.22–0.80] 0.001b
Female 128 (47.9) 0.28 ± 0.45 0.21 [0.04–0.73]
BMIc
Underweight 24 (9.0) 0.57 ± 0.42 0.69 [0.38–0.86] 0.047a
Normal 97 (36.3) 0.41 ± 0.42 0.46 [0.10–0.78]
Overweight 72 (27) 0.36 ± 0.45 0.43 [0.01–0.75]
Obese 63 (23.6) 0.29 ± 0.43 0.26 [0.03–0.73]
Education
No formal education 40 (15.0) 0.04 ± 0.41 0.06 [−0.21–0.22] <0.001a
Primary 71 (26.6) 0.36 ± 0.42 0.32 [0.08–0.74]
Secondary 102 (38.2) 0.45 ± 0.42 0.55 [0.16–0.79]
Graduated 54 (20.2) 0.50 ± 0.40 0.67 [0.23–0.84]
Household income (month)
High (more than 1000 JDd) 10 (3.7) 0.34 ± 0.48 0.28 [0.12–0.84] 0.109a
Moderate (400–1000 JD) 90 (33.7) 0.45 ± 0.43 0.64 [0.15–0.84]
Low (less than 400 JD) 167 (62.5) 0.33 ± 0.44 0.36 [0.03–0.72]
Residency 0.004a
Palestinian refugee camps 22 (8.2) 0.20 ± 0.39 0.15 [0.02–0.52]
Village 161 (60.3) 0.44 ± 0.44 0.58 [0.15–0.78]
City 84 (31.5) 0.29 ± 0.44 0.26 [0.02–0.73]
Living status
Alone 18 (6.7) 0.31 ± 0.37 0.28 [0.10–0.67] 0.347b
With family 249 (93.3) 0.38 ± 0.44 0.43 [0.07–0.77]
Marital status
Single, divorced, widowed 79 (29.6) 0.42 ± 0.44 0.48 [0.12–0.79] 0.171b
Married 188 (70.4) 0.35 ± 0.44 0.36 [0.07–0.75]
Occupation
Employed 35 (13.1) 0.51 ± 0.38 0.66 [0.21–0.88] 0.041b
Unemployed 232 (86.9) 0.35 ± 0.44 0.38 [0.06–0.75]
Smoking
Non-smoker 227 (85) 0.36 ± 0.44 0.36 [0.04–0.76] 0.156a
Light smoker 19 (7.1) 0.49 ± 0.48 0.64 [0.14–0.88]
Moderate smoker 17 (6.4) 0.53 ± 0.38 0.66 [0.28–0.78]
Heavy smoker 4 (1.5) 0.15 ± 0.46 0.10 [0.27–0.61]
Dialysis session duration (hours)
< 4 h 198 (74.2) 0.37 ± 0.45 0.41 [0.05–0.77] 0.859b
≥ 4 h 69 (25.8) 0.39 ± 0.42 0.41 [0.14–0.73]
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gender. One possible explanation is that poor social life
and physical inactivity of females in developing countries
might contribute to lower QOL scores, thus, females
tend to have poor QOL [50]. This observation is in
agreement with Merom et al [53] findings which
identified Palestinian women as being at the highest
risk of physical inactivity. Furthermore, males were
less likely to become anxious or depressed compared
to females [12, 54], thus, patients presented with
more symptoms of depression and anxiety indicated
lower levels of QOL [55–58]. The other possible ex-
planation for this result may be that females were
more obese in our study, which by itself worsens
HRQOL, as reported by Bossola et al. [59] and Feroze
et al. [54, 60]. According to our study, obese patients
were significantly associated with lower EQ-5D scores.
In the USA, a study conducted by Dwyer et al. [61]
also mentioned obesity as one of the factors associ-
ated with impaired HRQOL and recommended the
importance of keeping weight at healthier levels for
improvement of QOL.
This study found significant associations between high
education level and high HRQOL. This could be due to
the fact that educated patients may have a better under-
standing of the illness, its effects, and will themselves
benefit from the best management they can give [50], or
they have more information about the treatments,
greater self reported adherence, and a better relationship
with their healthcare team [58]. Education was also con-
firmed in several studies as an important discriminator
of HRQOL in HD patients [13, 62–64]. Our data showed
that being unemployed was significantly related to lower
EQ-5D scores. These results were in agreement with the
findings documented by Sakthong and Kasemsup [13].
Unemployment was also confirmed in several studies as
an important factor associated with impaired HRQOL in
HD patients [23, 32, 58].
According to our study, residency in a refugee camp
was also associated with low QOL with those living in a
village had the highest EQ-5D index. These results fur-
ther support the idea of closer communications and
stronger family ties among people in rural areas as found
by Saffari et al. [12] among Iranian population. A Lebanese
study demonstrated that rural residents had higher vitality
scores than urban residents [65]. However, it is hard to
compare our results with other studies since the health
care systems are different in different countries. Most of
Palestinians in refugees in the camps receive their care
from the UNRWA, and according to Eljedi et al. [66],
patients treated at the UNRWA clinics may have a poorer
quality of health care than patients getting care from other
providers. Residency in refugee camps, as an important
factor associated with impaired HRQOL, was also con-
firmed in several previous studies among different popula-
tions from Palestine such as diabetic or hypertensive
patients [36, 37, 43].
As for clinical factors, presence of co-morbid diseases
and increasing in the total number of medications have
been recognised as variables that were negatively associ-
ated with HRQOL. Presence of co-morbidity was nega-
tively associated with HRQOL. Similar associations were
observed in previous studies [12, 20, 24, 63]. Chronic
illnesses, mainly DM, were strongly associated with im-
paired HRQOL in ESRD patients on dialysis [67]. The
Table 2 EQ-5D total score by socio-demographic and clinical variables (n = 267) (Continued)
Dialysis vintage (years)
< 4 177 (66.3) 0.37 ± 0.44 0.39 [0.08–0.76] 0.806b
≥ 4 90 (33.7) 0.38 ± 0.44 0.47 [0.04–0.77]
Transplantation
Yes 26 (9.7) 0.52 ± 0.42 0.66 [0.33–0.84] 0.055b
No 241 (90.3) 0.36 ± 0.44 0.35 [0.05–0.75]
Total chronic co-morbid diseases
None 26 (9.7) 0.77 ± 0.29 0.81 [0.69–1.00] <0.001a
1 62 (23.2) 0.56 ± 0.39 0.69 [0.30–0.84]
2 63 (23.6) 0.41 ± 0.34 0.38 [0.18–0.73]
≥ 3 116 (43.4) 0.16 ± 0.43 0.15 [0.17–0.52]
Chronic medications
< 4 drugs/day 45 (16.9) 0.53 ± 0.37 0.67 [0.22–0.80] 0.010b
≥ 4 drugs/day 222 (83.1) 0.34 ± 0.44 0.33 [0.02–0.74]
Abbreviations: EQ-5D European Quality of Life scale 5 dimensions, JD Jordanian Dinar, BMI body mass index
aStatistical significance of differences calculated using the Kruskal-Wallis test
bStatistical significance of differences calculated using the Mann-Whitney U test
cData were missing from 11 patients
d1 Jordanian Dinar (JD) equals 1.41 US Dollar
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Table 3 EQ-VAS by socio-demographic and clinical characteristics
Variable EQ-VAS P-value
Mean ± SD Median [interquartile range]
Age category
< 30 59.95 ± 21.53 60 [50–80] 0.010a
30–60 60.28 ± 21.66 60 [50–75]
> 60 51.46 ± 23.20 50 [30–70]
Gender
Male 61.26 ± 19.94 60 [50–80] 0.002b
Female 52.41 ± 24.28 50 [40–70]
BMIc
Underweight 66.13 ± 16.44 65 [50–80] 0.198a
Normal 55.98 ± 21.92 60 [45–70]
Overweight 55.31 ± 24.68 50 [40–70]
Obese 58.25 ± 20.81 50 [45–70]
Smoking
Non smoker 55.96 ± 22.63 50 [45–70] 0.294a
Light smoker 64.47 ± 21.07 70 [50–80]
Moderate smoker 63.24 ± 22.29 60 [50–80]
Heavy smoker 55.00 ± 20.82 55 [35–75]
Education level
No formal education 50.63 ± 23.62 50 [40–70] 0.111a
Primary 54.72 ± 24.20 50 [40–70]
Secondary 59.79 ± 20.87 60 [50–70]
Graduated 59.54 ± 21.77 63 [50–80]
Household income (month)
High (more than 1000 JDd) 58.50 ± 20.00 55 [45–80] 0.968a
Moderate (400–1000 JD) 56.63 ± 22.05 58 [49–70]
Low (less than 400 JD) 57.14 ± 23.03 50 [50–72]
Residency
Palestinian refugee camps 62.5 ± 21.92 55 [50–80] 0.145a
Village 58.25 ± 21.99 60 [50–74]
City 53.21 ± 23.38 50 [40–70]
Living statues
Alone 57.50 ± 21.30 60 [50–70] 0.761b
With family 56.98 ± 22.65 50 [48–72]
Marital status
Single, divorced, widowed 55.78 ± 21.84 50 [50–70] 0.608b
Married 57.54 ± 22.85 60 [50–71]
Occupation
Employed 58.57 ± 21.54 60 [45–75] 0.509b
Unemployed 56.78 ± 22.71 50 [50–70]
Dialysis session duration (hours)
< 4 h 59.16 ± 51.11 50 [40–70] 0.163b
≥ 4 h 60.01 ± 22.13 60 [50–74]
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Table 3 EQ-VAS by socio-demographic and clinical characteristics (Continued)
Dialysis vintage (years)
< 4 55.86 ± 22.45 50 [50–70] 0.275b
≥ 4 66.30 ± 71.33 60 [49–80]
Transplantation
Yes 62.58 ± 19.54 68 [50–76] 0.212b
No 59.04 ± 47.35 50 [45–70]
Total chronic co-morbid diseases
None 63.15 ± 21.53 60 [50–80] 0.001a
1 62.82 ± 21.75 63 [50–80]
2 59.68 ± 21.04 65 [50–80]
≥ 3 56.53 ± 64.48 50 [40–70]
Chronic medications
< 4 drugs/day 63.56 ± 19.96 60 [50–80] 0.042b
≥ 4 drugs/day 58.54 ± 48.95 50 [40–70]
Abbreviation: EQ-VAS European Quality visual analogue scale, JD Jordanian Dinar, BMI body mass index
aStatistical significance of differences calculated using the Kruskal-Wallis test
bStatistical significance of differences calculated using the Mann-Whitney U test
cData were missing from 11 patients
d1 Jordanian Dinar (JD) equals 1.41 US Dollar
Table 4 Multiple linear regression analysis of association between factors and EQ-5D score
Variables Unstandardised coefficients (B) Standardised coefficients (Beta) P value 95 % CI for B
Age
Continuous (1-year units) −0.007 −0.272 <0.001 −0.010– −0.004
Gender
Male 0.154 0.177 0.001 0.064–0.244
Female Reference
BMI
Underweight or normal −0.034 −0.039 0.464 −0.124–0.057
Overweight or obese Reference
Education level
University 0.119 0.109 0.042 0.005–0.233
No formal, primary, secondary Reference
Residency
Village 0.121 0.136 0.007 0.033–0.210
Palestinian refugee camps or city Reference
Occupation
Employed 0.009 0.007 0.892 −0.124–0.142
Unemployed Reference
Number of co-morbid diseases
Continuous −0.089 −0.324 <0.001 −0.121– −0.056
Number of chronic medications
Continuous −0.018 −0.113 0.039 −0.034– −0.001
Abbreviations: EQ-5D European quality of life scale, SE standard error, BMI body mass index, CI confidence interval
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number of medications was significantly associated with
lower EQ-5D scores. These results were in agreement
with the findings reported by Chiu and colleagues
whereby people who took a large number of medications
rated their health as poorer than those who did not [68].
A negative impact of medication on HRQOL might be
mediated by the effect of medication-taking on patients’
behaviour due to high expense or side effects.
Strengths and limitations
This study had many strengths such as including a general-
ised sample of all HD centres in the West Bank, as well as
conducting face-to-face interviews to obtain more complete
data and high reliability of data collection. Furthermore,
our study is the first study assessing HRQOL among ESRD
patients in the West Bank and to the best of our knowledge
is the first one in Palestine that used the EQ-5D scale as a
measure. However, there were a number of limitations that
need to be noted. First, the cross-sectional nature of this
study makes it difficult to interpret any cause–effect rela-
tionship. Second, we used a convenience sampling tech-
nique that could decrease the generalisability of the results
to other HD patients. Third, data were collected via a face-
to-face interview which might have introduced interviewer’s
bias in the results. Lastly, additional clinical variables such
as albumin, calcium, and creatinine would help to get a
more complete view of possible dialysis outcome factors
related to HRQOL of HD patients.
Conclusions
Our results provide insight into a number of associations
between patient variables such as demographics, clinical
factors, and their HRQOL. Our research study reveals a
number of important results that can be taken into con-
sideration when dealing with HD patients. Elderly
patients, female gender, obese patients, patients with no
formal education, and living in Palestinian refugee camps
were all associated with poor HRQOL. In addition, this
study showed that lower HRQOL was associated with
higher numbers of chronic diseases as well as higher num-
bers of medications. These results are expected to be of
interest to educators, pharmacists, and clinicians working
with ESRD patients. Healthcare providers should be aware
of low HRQOL among patients with no formal education,
female gender, patient’s residents of refugee camps, mul-
tiple co-morbid diseases, multiple chronic medications,
and elderly patients to improve their QOL.
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